Thrombotic microangiopathy of hyperacute onset after autologous peripheral blood stem cell transplantation in malignant lymphoma

Bone Marrow Transplantation

Volumn 21, Issue 12, 1998, Pages 1263-1266

  Togitani, K ^a   Takeyama, K ^a   Yokozawa, T ^a   Andoh, M ^a   Narabayashi, M ^a   Kobayashi, Y ^a   Takenaka, T ^a   Tobinai, K ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

High dose chemotherapy; Hyperacute onset; PBSCT; Thrombotic microangiopathy

Indexed keywords

FRESH FROZEN PLASMA; GLUCOCORTICOID; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CASE REPORT; HEMATURIA; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LYMPHOMA; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0031824211     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701260     Document Type: Article

References (15)

1. Byrnes JJ, Hussein AM. Thrombotic microangiopathic syndromes after bone marrow transplantation. Cancer Invest 1996; 14: 151-157.
2. Pettitt AR, Clark RE. Thrombotic microangiopathy following bone marrow transplantation. Bone Marrow Transplant 1994; 14: 495-504.
3. Rodriguez MA. Cabanillas FC, Velasquez W et al. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol 1995; 13: 1734-1741.
4. Kohno A, Takeyama K, Narabayashi M et al. Low-dose granulocyte colony-stimulating factor enables the efficient collection of peripheral blood stem cells after disease-oriented, conventional-dose chemotherapy for breast cancer, malignant lymphoma and germ cell tumor. Bone Marrow Transplant 1995; 15: 49-54.
5. Fisher DC, Sherrill GB, Hussein et al. Thrombotic microangiopathy as a complication of high-dose chemotherapy for breast cancer. Bone Marrow Transplant 1996; 18: 193-198.
6. Juckett M, Perry EH, Daniels BS, Weisdorf DJ. Hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1991; 7: 405-409.
7. Ousler DP, Holley KE, Wagoner RD. Hemolytic uremic syndrome after bone marrow transplantation without total body irradiation. Am J Nephrol 1993; 13: 167-170.
8. Carlson K, Smedrnyl B, Hagberg H et al. Hemolytic uremic syndrome and renal dysfunction following BEAC (BCNU, etoposide, ara-C, cyclophosphamide) ± TBI and autologous BMT for malignant lymphomas. Bone Marrow Transplant 1993; 11: 205-208.
9. Lelie H, Baars JW, Rodenhuis S et al. Hemolytic uremic syn drome after high dose chemotherapy with autologous stem cell support. Cancer 1995; 76: 2338-2342.
10. Raybon KB, Snyder MJ, Halvorson RD. Hemolytic uremic syndrome after autologous BMT without TBI. Bone Marrow Transplant 1996; 17: 897-898.
11. Ohno E, Ohtsuka E, Iwashita T et al. Hemolytic uremic syndrome following autologous peripheral blood stem cell transplantation in a patient with malignant lymphoma. Bone Marrow Transplant 1997; 19: 1045-1047.
12. Zeigler ZR, Shadduck RK, Nath R, Andrew DF. Pilot study of combined cryosupernatant and protein A immunoabsorption exchange in the treatment of grade 3-4 bone marrow transplant-associated thrombotic microangiopathy. Bone Marrow Transplant 1996; 17: 81-86.
13. Doll DC, Ringenberg QS, Yarbro JW. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992; 19: 580-596.
14. Akizawa T, Koshikawa S, Ota K et al. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 1993; 64: 376-381.
15. Miyata T, Fujita Y. Inagi R et al. Effectiveness of nafamostat mesilate on glomerulonephritis in immune-complex diseases. Lancet 1993; 341: 1353.